3-(甲基硫代)-6-苯基-1,2,4-噻嗪-5(2H)-酮 | 1566-37-6

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 中文名称: 3-(甲基硫代)-6-苯基-1,2,4-噻嗪-5(2H)-酮
• 英文名称: 6-phenyl-3-methylmercapto-as-triazin-5-one
• 英文别名: 3-methylthio-6-phenyl-1,2,4-triazinone；3-Methylmercapto-6-phenyl-as-triazin-5(4H)-on；6-Phenyl-5-oxo-3-methylmercapto-1,2,4-triazin；3-Methylmercapto-5-oxo-6-phenyl-4,5-dihydro-as-triazin；3-methylsulfanyl-6-phenyl-4H-[1,2,4]triazin-5-one；3-Methylmercapto-6-phenyl-4H-[1,2,4]triazin-5-on；3-(methylthio)-6-phenyl-1,2,4-triazin-5(4H)-one；3-methylsulfanyl-6-phenyl-2H-1,2,4-triazin-5-one；3-methylsulfanyl-6-phenyl-4H-1,2,4-triazin-5-one
• CAS: 1566-37-6
• 化学式: C₁₀H₉N₃OS
• mdl: MFCD01185054
• 分子量: 219.267
• InChiKey: XHHHXWUBPUAMPZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  79.1
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2933699090

反应信息

• 作为反应物：
  描述：

  3-(甲基硫代)-6-苯基-1,2,4-噻嗪-5(2H)-酮 在 三氯氧磷 作用下， 生成 6-Phenyl-3,5-diamino-1,2,4-triazin
  参考文献：
  名称：

  DE951996

  摘要：

  公开号：
• 作为产物：
  描述：

  碘甲烷 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 16.0h， 生成 3-(甲基硫代)-6-苯基-1,2,4-噻嗪-5(2H)-酮
  参考文献：
  名称：

  TRIAZINE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC APPLICATION THEREOF

  摘要：

  该发明涉及一般式（I）的三嗪衍生物：其中R1、R2和R3如本文所定义。该发明还涉及制备这些三嗪衍生物的方法以及它们的治疗应用。

  公开号：

  US20080096891A1

文献信息

• ALICYCLIC HETEROCYCLIC COMPOUND
  申请人：Mitsubishi Tanabe Pharma Corporation

  公开号：EP1970373A1

  公开（公告）日：2008-09-17

  An alicyclic heterocyclic compound represented by the following formula or a pharmaceutically acceptable salt thereof: wherein ring A is a heterocyclic ring, ring B is a carbocyclic ring, a heterocyclic ring etc., P1 and P2 are CH or N, q and r are 0 to 2, X is -NH-, -O-, -CH2-, etc., Y is -CH2-, -CO-, -SO2-, etc., Z is -CO-, -SO2-, etc., and R3 is carbocyclic group, heterocyclic group, hydroxyl, alkoxy or amino, is useful as a controlling agent of the function of CCR4 useful for the prevention or treatment for bronchial asthma, atopic dermatitis, etc.

  以下是该公式表示的脂环杂环化合物或其药用可接受盐： 其中环A是杂环，环B是碳环，杂环等，P1和P2是CH或N，q和r为0至2，X为-NH-，-O-，-CH2-等，Y为-CH2-，-CO-，-SO2-等，Z为-CO-，-SO2-等，R3为碳环基团，杂环基团，羟基，烷氧基或氨基， 可用作CCR4功能的控制剂，用于预防或治疗支气管哮喘，特应性皮炎等。
• TRIAZOLOTRIAZINES AS KINASE INHIBITORS
  申请人：Zhuo Jincong

  公开号：US20080039457A1

  公开（公告）日：2008-02-14

  The present invention is directed to [1,2,4]triazolo[4,3-b][1,2,4]triazines, and pharmaceutical compositions thereof, which are inhibitors of kinases such as c-Met and are useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways.

  本发明涉及[1,2,4]三唑并[4,3-b][1,2,4]三嗪，以及其药物组合物，这些化合物是c-Met等激酶的抑制剂，可用于治疗癌症和其他与激酶通路失调相关的疾病。
• Triazolotriazines as kinase inhibitors
  申请人：Incyte Corporation

  公开号：US07915408B2

  公开（公告）日：2011-03-29

  The present invention is directed to [1,2,4]triazolo[4,3-b][1,2,4]triazines, and pharmaceutical compositions thereof, which are inhibitors of kinases such as c-Met and are useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways.

  本发明涉及[1,2,4]三唑[4,3-b][1,2,4]三嗪以及其制药组合物，其为c-Met酪氨酸激酶抑制剂，可用于治疗癌症和其他与激酶通路失调相关的疾病。
• Alicyclic Heterocyclic Compound
  申请人：Furukubo Shigeru

  公开号：US20090182140A1

  公开（公告）日：2009-07-16

  An alicyclic heterocyclic compound represented by the following formula or a pharmaceutically acceptable salt thereof: wherein ring A is a heterocyclic ring, ring B is a carbocyclic ring, a heterocyclic ring etc., P 1 and P 2 are CH or N, q and r are 0 to 2, X is —NH—, —O—, —CH 2 —, etc., Y is —CH 2 —, —CO—, —SO 2 —, etc., Z is —CO—, —SO 2 —, etc., and R 3 is carbocyclic group, heterocyclic group, hydroxyl, alkoxy or amino, is useful as a controlling agent of the function of CCR 4 useful for the prevention or treatment for bronchial asthma, atopic dermatitis, etc.

  以下式子所示的脂环杂环化合物或其药学上可接受的盐： 其中环A为杂环，环B为碳环，杂环等，P1和P2为CH或N，q和r为0至2，X为—NH—，—O—，—CH2—等，Y为—CH2—，—CO—，—SO2—等，Z为—CO—，—SO2—等，R3为碳环基团，杂环基团，羟基，烷氧基或氨基，用作CCR4功能调节剂，用于预防或治疗支气管哮喘，特应性皮炎等。
• Design, synthesis and biological evaluation of 2-aminopyrimidinones and their 6-aza-analogs as a new class of CK2 inhibitors
  作者：Maksym O. Chekanov、Olga V. Ostrynska、Sergii S. Tarnavskyi、Anatoliy R. Synyugin、Nadiia V. Briukhovetska、Volodymyr G. Bdzhola、Alexander E. Pashenko、Andrey A. Fokin、Sergiy M. Yarmoluk

  DOI：10.3109/14756366.2013.837898

  日期：2014.10.1

  In order to find the new potent CK2 inhibitors the 60 derivatives of 2-aminopyrimidinone and their 6-aza-substituted analogs were synthesized and tested in vitro. Among them, the most efficient inhibitor 2-hydroxy-5-[4-(4-methoxyphehyl)-6-oxo-1,6-dihydropyrimidin-2-ylamino] benzoic acid was identified (IC50 = 1.1 mu M). The structure-activity relationship study of newly synthesized derivatives was carried out and their binding mode with adenosine triphosphate-acceptor site of CK2 was proposed.